BiotechTube

SAR445088

Phase 1Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Haemolytic Anaemia

Conditions

Autoimmune Haemolytic Anaemia

Trial Timeline

Mar 22, 2021 → Mar 4, 2025

NCT ID
NCT04802057

About SAR445088

SAR445088 is a phase 1 stage product being developed by Sanofi for Autoimmune Haemolytic Anaemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04802057. Target conditions include Autoimmune Haemolytic Anaemia.

What happened to similar drugs?

0 of 13 similar drugs in Autoimmune Haemolytic Anaemia were approved

Approved (0) Terminated (3) Active (10)
🔄SatralizumabChugai PharmaceuticalPhase 3
🔄Enteric-coated Mycophenolate SodiumNovartisPhase 3
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
🔄rilzabrutinib + placeboSanofiPhase 3
❌parsaclisinib + placeboIncytePhase 3
❌Intravenous Immunoglobulin + Placebos + Normal SalineGrifolsPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04802057Phase 1Terminated

Competing Products

20 competing products in Autoimmune Haemolytic Anaemia

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
47
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
Enteric-coated Mycophenolate SodiumNovartisPhase 3
40
Ianalumab + PlaceboNovartisPhase 3
44
VAY736NovartisPhase 2/3
38
remibrutinibNovartisPhase 1
29
RO7049665RochePhase 2
27
rituximab (Mabthera®) + PlaceboRochePhase 3
40
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
42
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
35
BMS-986165Bristol Myers SquibbPhase 1
29
NivolumabBristol Myers SquibbPhase 1
21
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
36
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
29
BIVV020SanofiPhase 1
29
rilzabrutinibSanofiPhase 2
39
rilzabrutinib + placeboSanofiPhase 3
47